Last reviewed · How we verify
NCT04537442
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 trial testing IM21 CAR-T cells in Multiple Myeloma in 10 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 3 September 2020 |
| Primary completion | 30 December 2022 |
| Estimated completion | 2 March 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- IM21 CAR-T cells — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd. — full company profile →
Who can join
60 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center study to assess the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma in China.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2 -
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT, Ye JC. · · 2021 · cited 21× · PMID 34301270 · DOI 10.1186/s13045-021-01109-y -
Targeting immunosenescence for improved tumor immunotherapy.
Liu Z, Zuo L, Zhou Z, Liu S, et al · · 2024 · cited 16× · PMID 39473905 · DOI 10.1002/mco2.777 -
Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies.
Lin WY, Wang HH, Chen YW, Lin CF, et al · · 2020 · cited 13× · PMID 33212810 · DOI 10.3390/ijms21228655 -
Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion.
Wang T, He T, Ma L, Yang Y, et al · · 2022 · cited 12× · PMID 35651792 · DOI 10.3389/fonc.2022.854448 -
BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
Wang T, Yang Y, Ma L, Feng R, et al · · 2024 · cited 6× · PMID 39313307 · DOI 10.1136/jitc-2024-009476 -
The Role of Senescence, its Therapeutic Relevance and Clinical Implications in the Tumor Microenvironment.
Shi H, Xiao M, Li Y, Liu X, et al · · 2025 · cited 2× · PMID 40860134 · DOI 10.7150/thno.112633
Verify or expand the search:
- PubMed search for NCT04537442
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IM21 CAR-T cells
Trials testing the same drug.
- NCT05478343 — Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mu · EARLY_PHASE1 · unknown
- NCT03711864 — Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma · Phase 1 · unknown
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Beijing Immunochina Medical Science & Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT07406984 — Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction · Phase 1 · not yet recruiting
- NCT06886919 — Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus · EARLY_PHASE1 · not yet recruiting
- NCT06852573 — Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus · Phase 1 · not yet recruiting
- NCT06718738 — Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer · Phase 1 · recruiting
- NCT06690359 — IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04537442 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Immunochina Medical Science & Technology Co., Ltd.
- Last refreshed: 3 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04537442.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing